{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:28:30Z","timestamp":1792639710655,"version":"4.5.0"},"reference-count":94,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T00:00:00Z","timestamp":1648166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>There is a close relationship between diabetes mellitus and heart failure, and diabetes is an independent risk factor for heart failure. Diabetes and heart failure are linked by not only the complication of ischemic heart disease, but also by metabolic disorders such as glucose toxicity and lipotoxicity based on insulin resistance. Cardiac dysfunction in the absence of coronary artery disease, hypertension, and valvular disease is called diabetic cardiomyopathy. Diabetes-induced hyperglycemia and hyperinsulinemia lead to capillary damage, myocardial fibrosis, and myocardial hypertrophy with mitochondrial dysfunction. Lipotoxicity with extensive fat deposits or lipid droplets is observed on cardiomyocytes. Furthermore, increased oxidative stress and inflammation cause cardiac fibrosis and hypertrophy. Treatment with a sodium glucose cotransporter 2 (SGLT2) inhibitor is currently one of the most effective treatments for heart failure associated with diabetes. However, an effective treatment for lipotoxicity of the myocardium has not yet been established, and the establishment of an effective treatment is needed in the future. This review provides an overview of heart failure in diabetic patients for the clinical practice of clinicians.<\/jats:p>","DOI":"10.3390\/ijms23073587","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T15:31:21Z","timestamp":1648222281000},"page":"3587","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":265,"title":["Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8845-3626","authenticated-orcid":false,"given":"Kazufumi","family":"Nakamura","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9039-3439","authenticated-orcid":false,"given":"Toru","family":"Miyoshi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Akagi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Ejiri","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoaki","family":"Matsuo","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keishi","family":"Ichikawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Iwasaki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7347-685X","authenticated-orcid":false,"given":"Takanori","family":"Naito","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Namba","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3842-2412","authenticated-orcid":false,"given":"Masatoki","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Okayama Saiseikai General Hospital, Okayama 700-8511, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0002-9149(74)90089-7","article-title":"Role of diabetes in congestive heart failure: The Framingham study","volume":"34","author":"Kannel","year":"1974","journal-title":"Am. J. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1161\/CIRCULATIONAHA.115.015357","article-title":"Diabetic cardiomyopathy: Catabolism driving metabolism","volume":"131","author":"Wang","year":"2015","journal-title":"Circulation"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3904\/kjim.2016.208","article-title":"Diabetic cardiomyopathy: Where we are and where we are going","volume":"32","author":"Lee","year":"2017","journal-title":"Korean J. Intern. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","article-title":"Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity","volume":"122","author":"Jia","year":"2018","journal-title":"Circ. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1161\/CIRCRESAHA.118.314665","article-title":"Diabetic Cardiomyopathy","volume":"124","author":"Dillmann","year":"2019","journal-title":"Circ. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1253\/circj.CJ-13-1564","article-title":"Diabetes-related heart failure","volume":"78","author":"Bando","year":"2014","journal-title":"Circ. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1590\/1806-9282.65.1.69","article-title":"Diabetic cardiomyopathy: Factual or factoid?","volume":"65","author":"Quinaglia","year":"2019","journal-title":"Rev. Assoc. Med. Bras."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1113\/JP276747","article-title":"Cardiomyopathy in obesity, insulin resistance and diabetes","volume":"598","author":"Nakamura","year":"2020","journal-title":"J. Physiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0002-9149(72)90595-4","article-title":"New type of cardiomyopathy associated with diabetic glomerulosclerosis","volume":"30","author":"Rubler","year":"1972","journal-title":"Am. J. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/eurheartj\/ehm342","article-title":"Classification of the cardiomyopathies: A position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"29","author":"Elliott","year":"2008","journal-title":"Eur. Heart J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1172\/JCI108843","article-title":"Evidence for cardiomyopathy in familial diabetes mellitus","volume":"60","author":"Regan","year":"1977","journal-title":"J. Clin. Investig."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.289.2.194","article-title":"Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic","volume":"289","author":"Redfield","year":"2003","journal-title":"JAMA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1161\/CIRCULATIONAHA.106.679597","article-title":"Diabetic cardiomyopathy revisited","volume":"115","author":"Boudina","year":"2007","journal-title":"Circulation"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/cvr\/cvr212","article-title":"Lipotoxicity in type 2 diabetic cardiomyopathy","volume":"92","author":"Schrauwen","year":"2011","journal-title":"Cardiovasc. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1161\/CIRCRESAHA.118.314607","article-title":"Mitophagy is Essential for Maintaining Cardiac Function During High Fat Diet-Induced Diabetic Cardiomyopathy","volume":"124","author":"Tong","year":"2019","journal-title":"Circ. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1161\/CIRCRESAHA.118.311371","article-title":"Heart Failure in Type 2 Diabetes Mellitus","volume":"124","author":"Kenny","year":"2019","journal-title":"Circ. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.yjmcc.2015.12.011","article-title":"Diabetes-associated cardiac fibrosis: Cellular effectors, molecular mechanisms and therapeutic opportunities","volume":"90","author":"Russo","year":"2016","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10741-013-9374-y","article-title":"Advanced glycation end products: Role in pathology of diabetic cardiomyopathy","volume":"19","author":"Bodiga","year":"2014","journal-title":"Heart. Fail. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Grubic Rotkvic, P., Planinic, Z., Liberati Prso, A.M., Sikic, J., Galic, E., and Rotkvic, L. (2021). The Mystery of Diabetic Cardiomyopathy: From Early Concepts and Underlying Mechanisms to Novel Therapeutic Possibilities. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115973"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.120.315913","article-title":"Basic Mechanisms of Diabetic Heart Disease","volume":"126","author":"Ritchie","year":"2020","journal-title":"Circ. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1536\/ihj.20-537","article-title":"Electron Microscopy Revealed Massive Lipid Droplets in Cardiomyocytes in a Patient with Cardiogenic Shock Following a Fulminant Type 1 Diabetes Mellitus","volume":"62","author":"Sugawara","year":"2021","journal-title":"Int. Heart J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1253\/circj.CJ-08-1012","article-title":"Cardiac adiposity and global cardiometabolic risk: New concept and clinical implication","volume":"73","author":"Shimabukuro","year":"2009","journal-title":"Circ. J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jacc.2012.11.062","article-title":"Association of epicardial fat with cardiovascular risk factors and incident myocardial infarction in the general population: The Heinz Nixdorf Recall Study","volume":"61","author":"Mahabadi","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1161\/CIRCULATIONAHA.111.060889","article-title":"Ventricular assist device implantation corrects myocardial lipotoxicity, reverses insulin resistance, and normalizes cardiac metabolism in patients with advanced heart failure","volume":"125","author":"Chokshi","year":"2012","journal-title":"Circulation"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1194\/jlr.M800147-JLR200","article-title":"Ceramide is a cardiotoxin in lipotoxic cardiomyopathy","volume":"49","author":"Park","year":"2008","journal-title":"J. Lipid. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"H2096","DOI":"10.1152\/ajpheart.00452.2009","article-title":"Type 1 diabetic cardiomyopathy in the Akita (Ins2WT\/C96Y) mouse model is characterized by lipotoxicity and diastolic dysfunction with preserved systolic function","volume":"297","author":"Basu","year":"2009","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1172\/JCI9056","article-title":"Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth","volume":"105","author":"Barger","year":"2000","journal-title":"J. Clin. Investig."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"166044","DOI":"10.1016\/j.bbadis.2020.166044","article-title":"Diabetic fibrosis","volume":"1867","author":"Tuleta","year":"2021","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pharmthera.2016.11.013","article-title":"Cardiac oxidative stress in diabetes: Mechanisms and therapeutic potential","volume":"172","author":"Faria","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5913374","DOI":"10.1155\/2022\/5913374","article-title":"Oxidative Stress Signaling Mediated Pathogenesis of Diabetic Cardiomyopathy","volume":"2022","author":"Tang","year":"2022","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.freeradbiomed.2022.01.028","article-title":"Protective role of hydrogen sulfide against diabetic cardiomyopathy via alleviating necroptosis","volume":"181","author":"Gong","year":"2022","journal-title":"Free Radic. Biol. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"750382","DOI":"10.3389\/fcell.2021.750382","article-title":"Mitophagy in Diabetic Cardiomyopathy: Roles and Mechanisms","volume":"9","author":"Zheng","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41419-017-0135-z","article-title":"Cellular death, reactive oxygen species (ROS) and diabetic complications","volume":"9","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Luo, B., Li, B., Wang, W., Liu, X., Xia, Y., Zhang, C., Zhang, M., Zhang, Y., and An, F. (2014). NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0104771"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1210\/en.2017-00294","article-title":"Aldose Reductase Mediates NLRP3 Inflammasome-Initiated Innate Immune Response in Hyperglycemia-Induced Thp1 Monocytes and Male Mice","volume":"158","author":"Pal","year":"2017","journal-title":"Endocrinology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.7150\/ijbs.33568","article-title":"Role of Pyroptosis in Cardiovascular Diseases and its Therapeutic Implications","volume":"15","author":"Zeng","year":"2019","journal-title":"Int. J. Biol. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.2337\/diabetes.53.12.3201","article-title":"Decreased sarcoplasmic reticulum activity and contractility in diabetic db\/db mouse heart","volume":"53","author":"Belke","year":"2004","journal-title":"Diabetes"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/cvr\/cvm001","article-title":"Dyslipidaemia in type II diabetic mice does not aggravate contractile impairment but increases ventricular stiffness","volume":"77","author":"Vanderper","year":"2008","journal-title":"Cardiovasc. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"251","DOI":"10.14797\/mdcj-14-4-251","article-title":"Cardiac Autonomic Neuropathy in Diabetes Mellitus","volume":"14","author":"Agashe","year":"2018","journal-title":"Methodist Debakey Cardiovasc. J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1161\/01.CIR.92.11.3212","article-title":"Endothelial control of arterial distensibility is impaired in chronic heart failure","volume":"92","author":"Ramsey","year":"1995","journal-title":"Circulation"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/01.CIR.0000153349.77489.CF","article-title":"Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure","volume":"111","author":"Katz","year":"2005","journal-title":"Circulation"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jjcc.2015.12.001","article-title":"Postprandial hyperlipidemia as a potential residual risk factor","volume":"67","author":"Nakamura","year":"2016","journal-title":"J. Cardiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.2337\/diabetes.52.11.2795","article-title":"Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: The role of protein kinase C and NAD(P)H-oxidase activation","volume":"52","author":"Quagliaro","year":"2003","journal-title":"Diabetes"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.2337\/db15-0655","article-title":"Comment on Nolan et al. Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes","volume":"64","author":"Taegtmeyer","year":"2015","journal-title":"Diabetes"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/ncpendmet0046","article-title":"Mechanisms of disease: Pathway-selective insulin resistance and microvascular complications of diabetes","volume":"1","author":"Groop","year":"2005","journal-title":"Nat. Clin. Pract. Endocrinol. Metab."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1007\/s00125-011-2141-5","article-title":"Repetitive hypoglycaemia increases serum adrenaline and induces monocyte adhesion to the endothelium in rat thoracic aorta","volume":"54","author":"Jin","year":"2011","journal-title":"Diabetologia"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.metabol.2008.10.018","article-title":"Proinflammatory cytokines in response to insulin-induced hypoglycemic stress in healthy subjects","volume":"58","author":"Kitabchi","year":"2009","journal-title":"Metabolism"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12933-020-01132-2","article-title":"Combination therapy with pemafibrate (K-877) and pitavastatin improves vascular endothelial dysfunction in dahl\/salt-sensitive rats fed a high-salt and high-fat diet","volume":"19","author":"Yoshida","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacc.2009.04.049","article-title":"Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes","volume":"54","author":"Aguilar","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.ahj.2011.07.030","article-title":"Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: Evidence from a 37,229 patient meta-analysis","volume":"162","author":"Castagno","year":"2011","journal-title":"Am. Heart J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"d4169","DOI":"10.1136\/bmj.d4169","article-title":"Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: Meta-analysis of randomised controlled trials","volume":"343","author":"Boussageon","year":"2011","journal-title":"BMJ"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.cmet.2018.02.019","article-title":"Metabolic Slowing and Reduced Oxidative Damage with Sustained Caloric Restriction Support the Rate of Living and Oxidative Damage Theories of Aging","volume":"27","author":"Redman","year":"2018","journal-title":"Cell Metab."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"b4731","DOI":"10.1136\/bmj.b4731","article-title":"Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: Retrospective cohort study using UK general practice research database","volume":"339","author":"Tzoulaki","year":"2009","journal-title":"BMJ"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(07)61514-1","article-title":"Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: A meta-analysis of randomised clinical trials","volume":"370","author":"Lago","year":"2007","journal-title":"Lancet"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12933-015-0242-z","article-title":"Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: Results of the 3D trial","volume":"14","author":"Oe","year":"2015","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Investigators, Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1161\/CIRCRESAHA.118.312673","article-title":"Do DPP-4 Inhibitors Cause Heart Failure Events by Promoting Adrenergically Mediated Cardiotoxicity? Clues From Laboratory Models and Clinical Trials","volume":"122","author":"Packer","year":"2018","journal-title":"Circ. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1161\/CIRCHEARTFAILURE.112.000162","article-title":"Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: Systematic review of observational studies involving 34,000 patients","volume":"6","author":"Eurich","year":"2013","journal-title":"Circ. Heart Fail."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1007\/s00125-010-1906-6","article-title":"Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: A retrospective nationwide cohort study","volume":"53","author":"Andersson","year":"2010","journal-title":"Diabetologia"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1161\/CIRCRESAHA.108.190918","article-title":"Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure","volume":"104","author":"Gundewar","year":"2009","journal-title":"Circ. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1161\/CIRCULATIONAHA.108.798561","article-title":"Metformin prevents progression of heart failure in dogs: Role of AMP-activated protein kinase","volume":"119","author":"Sasaki","year":"2009","journal-title":"Circulation"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1253\/circj.CJ-19-0342","article-title":"JCS 2017\/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure- Digest Version","volume":"83","author":"Tsutsui","year":"2019","journal-title":"Circ. J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11936-017-0522-x","article-title":"Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond","volume":"19","author":"Martens","year":"2017","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jjcc.2017.12.004","article-title":"A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity","volume":"71","author":"Sano","year":"2018","journal-title":"J. Cardiol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Szekeres, Z., Toth, K., and Szabados, E. (2021). The Effects of SGLT2 Inhibitors on Lipid Metabolism. Metabolites, 11.","DOI":"10.3390\/metabo11020087"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Takata, T., and Isomoto, H. (2021). Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Renoprotective Mechanisms beyond Glycemic Control. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094374"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1536\/ihj.18-392","article-title":"Inhibitory Effects of Tofogliflozin on Cardiac Hypertrophy in Dahl Salt-Sensitive and Salt-Resistant Rats Fed a High-Fat Diet","volume":"60","author":"Kimura","year":"2019","journal-title":"Int. Heart J."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/1440-1681.12725","article-title":"Effect of a selective SGLT2 inhibitor, luseogliflozin, on circadian rhythm of sympathetic nervous function and locomotor activities in metabolic syndrome rats","volume":"44","author":"Rahman","year":"2017","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1097\/HJH.0000000000001434","article-title":"Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2","volume":"35","author":"Matthews","year":"2017","journal-title":"J. Hypertens."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/jdi.12726","article-title":"Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin: Subanalysis of placebo-controlled, double-blind clinical trials","volume":"9","author":"Sano","year":"2018","journal-title":"J. Diabetes Investig."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1161\/CIRCULATIONAHA.121.053350","article-title":"Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium\/Glucose Cotransporter 2 Inhibitor Empagliflozin","volume":"143","author":"Philippaert","year":"2021","journal-title":"Circulation"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.tcm.2015.05.006","article-title":"Late sodium current: A mechanism for angina, heart failure, and arrhythmia","volume":"26","author":"Makielski","year":"2016","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"11587","DOI":"10.1002\/jcp.27791","article-title":"Ranolazine prevents pressure overload-induced cardiac hypertrophy and heart failure by restoring aberrant Na(+) and Ca(2+) handling","volume":"234","author":"Nie","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.yjmcc.2009.04.003","article-title":"Diastolic transient inward current in long QT syndrome type 3 is caused by Ca2+ overload and inhibited by ranolazine","volume":"47","author":"Lindegger","year":"2009","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Investigators, Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e015103","DOI":"10.1161\/JAHA.119.015103","article-title":"Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus","volume":"9","author":"Ejiri","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1093\/eurheartj\/ehab715","article-title":"The EMPEROR-Preserved study: End of the search for the \u201cPhoenix\u201d or beginning of a new season for trials in heart failure with preserved ejection fraction","volume":"42","author":"Volpe","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"449","DOI":"10.14740\/jocmr3014w","article-title":"Is an Increase in Serum Magnesium One of the Causes of Cardiovascular Events Reduction in the EMPA-REG OUTCOME Study?","volume":"9","author":"Yanagawa","year":"2017","journal-title":"J. Clin. Med. Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1475-2840-11-23","article-title":"Low serum magnesium concentrations are associated with a high prevalence of premature ventricular complexes in obese adults with type 2 diabetes","volume":"11","author":"Song","year":"2012","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"14872","DOI":"10.1038\/s41598-018-33293-2","article-title":"Empagliflozin Ammeliorates High Glucose Induced-Cardiac Dysfuntion in Human iPSC-Derived Cardiomyocytes","volume":"8","author":"Ng","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"m4573","DOI":"10.1136\/bmj.m4573","article-title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: Systematic review and network meta-analysis of randomised controlled trials","volume":"372","author":"Palmer","year":"2021","journal-title":"BMJ"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/7\/3587\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:43:21Z","timestamp":1760136201000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/7\/3587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,25]]},"references-count":94,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["ijms23073587"],"URL":"https:\/\/doi.org\/10.3390\/ijms23073587","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,25]]}}}